Our MG community took note of the recent news regarding the latest therapy options that aim to reduce the burden of hours-long treatment delivery with IVIG. For those who are responding well to this new treatment, it’s a game changer. But we recognize that many patients are interesting in learning more, so here are some questions that have come in from the MG community with answers provided by Dr. Betty Soliven of the University of Chicago School of Medicine and a member of our Medical Advisory Board. [Click here to read more.]
Recent Posts
- New generic version of Mestinon as oral syrup available in U.S.
- Read study results on patient perceptions of disease burden and treatment of myasthenia gravis based on sentiment analysis of digital conversations
- Ask An Expert – What you should know about the newest therapy options.
- Conquer MG is seeking new Board of Trustees
- Untold Stories: Life with Myasthenia Gravis – A podcast
Blog Archives
- April 2024
- September 2023
- July 2023
- May 2023
- February 2023
- December 2022
- October 2022
- September 2022
- July 2022
- April 2022
- January 2022
- July 2021
- May 2021
- March 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- February 2020
- January 2020
- November 2019
- October 2019
- August 2019
- July 2019
- March 2019
- February 2019
- December 2018
- September 2018
- March 2018
- February 2018
- December 2017
- August 2017
- June 2017
- May 2017
- January 2017
- September 2016
- August 2016
- June 2016
- March 2016
- January 2016
- November 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- February 2015
- January 2015